Neil A. Came

St Andrew's Place
East Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Journal: Internal medicine journal

Published: November 01, 2025

Detecting T-cell clones of uncertain significance using anti-TRBC1-based flow cytometry.

Detecting T-cell clones of uncertain significance using anti-TRBC1-based flow cytometry.

Journal: Pathology

Published: September 22, 2025

Computational flow cytometry reveals a high prevalence of TRBC1-restricted CD8+ T-cell subsets.

Computational flow cytometry reveals a high prevalence of TRBC1-restricted CD8+ T-cell subsets.

Journal: Leukemia & lymphoma

Published: March 31, 2025

Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.

Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.

Journal: British journal of haematology

Published: February 03, 2024

Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.

Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.

Journal: British journal of haematology

Published: September 07, 2023

Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.

Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: December 06, 2022

Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.

Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.

Journal: Cytometry. Part B, Clinical cytometry

Published: July 28, 2021

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.

Journal: Pathology

Published: November 29, 2020

A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.

A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.

Journal: British journal of haematology

Published: April 24, 2020

Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.

Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.

Journal: Cytometry. Part B, Clinical cytometry

Published: November 22, 2019

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

Journal: Blood advances

Published: August 19, 2019

Should we be routinely testing for circulating clonal plasma cells in patients with multiple myeloma?

Should we be routinely testing for circulating clonal plasma cells in patients with multiple myeloma?

Journal: Cytometry. Part B, Clinical cytometry

Published: September 22, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026